Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA

Ying Zhang1, Shuhua Tong1, Li Wan1

  • 1Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

PubMed
Abstract

Insights

First-generation KRAS inhibitors, sotorasib and adagrasib, show specific adverse events like diarrhea and hepatotoxicity. This analysis highlights the need for careful patient monitoring during cancer treatment.

Area of Science:

  • Oncology
  • Pharmacovigilance
  • Drug Safety

Background:

  • Sotorasib and adagrasib are approved first-generation KRAS inhibitors for specific cancers.
  • This study evaluates adverse events (AEs) associated with these KRAS inhibitors using FAERS data.

Purpose of the Study:

  • To assess the safety profile of sotorasib and adagrasib.
  • To identify potential new adverse event signals for KRAS inhibitors.

Main Methods:

  • Utilized the FAERS database for adverse event reporting.
  • Applied four disproportionality analysis methods: ROR, PRR, BCPNN, and MGPS.
  • Analyzed 5,580 AEs from 2,958 reports between Q2 2021 and Q1 2024.

Main Results:

  • Identified 43 and 18 disproportionate reporting items for sotorasib and adagrasib, respectively.
  • Common AEs included diarrhea, hepatotoxicity, and pneumonitis.
  • Unexpected AEs such as pericardial effusion (sotorasib) and seizure (adagrasib) were noted, with most occurring within the first month of treatment.

Conclusions:

  • The study provides a comprehensive safety profile for KRAS inhibitors.
  • Highlights the emergence of new AE signals, underscoring the need for vigilant monitoring and supportive care in patients receiving these treatments.

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
735
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
429
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K